Subscribe to Newsletter

Precision medicine

Outside the Lab Clinical care

The “We” in Team

| Judith Hugh

What exactly is a multidisciplinary team – and what is the pathologist’s role in it?

Inside the Lab Clinical care

From Dream to Deployment

| Sponsored by Leica Biosystems

Leeds Teaching Hospitals NHS Trust and Leica Biosystems have formed a unique partnership to make a 100% digital pathology service a reality

Inside the Lab Clinical care

Leading the Pack

| Marisa Saint Martin

Pathologists hold the key to diagnostic management teams – and diagnostic management teams have a lot to contribute to patient care

Outside the Lab Biochemistry and molecular biology

Pre-Empting Relapse

| Luke Turner

A new DNA test that can detect treatment-resistant mutations could prove crucial for patients with acute myeloid leukemia, providing an early indication that targeted therapeutic intervention is needed

Inside the Lab Clinical care

Gone Fishing

A combination of magnetic particles that bind circulating tumor cells and a magnetic wire that samples them directly from the vein could lead to earlier diagnosis

Inside the Lab Clinical care

Characterizing Cancer

| Luke Turner

Digital spatial profiling technology may enable researchers to identify biomarkers that indicate how patients with high-risk melanoma will respond to treatment

Outside the Lab Digital and computational pathology

Intelligent Pharma Partners

| Holger Lange and Cris Luengo

How combining their efforts with those of the pharmaceutical industry can help pathologists make a business case for AI

Outside the Lab Biochemistry and molecular biology

Fighting Resistance in Bloodstream Infections

| Luke Turner

When bacteria become resistant to the last line of defense, rapid detection and treatment is more important than ever. A new assay can help with treatment selection for carbapenem-resistant infections

Inside the Lab Companion diagnostics

Fluid Evidence

Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment

Outside the Lab Clinical care

Better Biomarkers for AD R&D

| Carlo Medici

For better diagnosis and monitoring of Alzheimer’s disease, as well as drug R&D, we need to move toward widespread use of MRI biomarker imaging, even if blood screening tests become a reality

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register